Excitation functions of the Ho(He,xn)Tm and Ti(He,x)V,Cr reactions.

The cross-sections of the Ti(He,x)V,Cr and the Ho(He,xn)Tm reactions were measured from the threshold to 47 MeV using well-established method of stacked-foil activation and off-line γ-ray spectrometry. The He-ion induced nuclear reaction cross-sections on Ho were measured for the first time. Their comparison with the prediction adopted from the TENDL-2017 library revealed significant difference.

Radiolabeling of the antibody IgG M75 for epitope of human carbonic anhydrase IX by Cu and Cu and its biological testing.

Human carbonic anhydrase IX is a membrane enzyme that is significantly expressed in some types of cancer cells, while copper radioisotopes offer wide range of diagnostic, therapeutic and theranostic properties. The work was focused on a new approach to the labelling of antibody IgG M75 for epitope human carbonic anhydrase IX with copper radioisotopes Cu and Cu and its in vivo testing in mice with inoculated colorectal cancer. Monoclonal antibody IgG M75 for epitope human carbonic anhydrase IX was successfully conjugated with copper-specific chelator "phosphinate" and labelled with Cu and Cu The obtained molecule has considerable potential as a radioimmuno pharmaceutical suitable for imaging of tumours expressing carbonic anhydrase IX by positron emission tomography (PET).

In vitro evaluation of the monoclonal antibody Cu-IgG M75 against human carbonic anhydrase IX and its in vivo imaging.

Specific oncology diagnostics requires new types of the selective radiopharmaceuticals, particularly those suitable for the molecular PET imaging. The aim of this work is to present a new, specific PET-immunodiagnostic radiopharmaceutical based on the monoclonal antibody IgG M75 targeting human carbonic anhydrase IX labelled with Cu (T = 12.70h) and its in vitro and in vivo evaluation.

Boosting nanodiamond fluorescence: towards development of brighter probes.

A novel approach for preparation of ultra-bright fluorescent nanodiamonds (fNDs) was developed and the thermal and kinetic optimum of NV center formation was identified. Combined with a new oxidation method, this approach enabled preparation of particles that were roughly one order of magnitude brighter than particles prepared with commonly used procedures.

Assessment of radionuclidic impurities in cyclotron produced (99m)Tc.

Introduction: The commercial viability of cyclotron-produced (99m)Tc as an alternative to generator-produced (99m)Tc depends on several factors. These include: production yield, ease of target processing and recycling of (100)Mo, radiochemical purity, specific activity as well as the presence of other radionuclides, particularly various Tc radioisotopes that cannot be separated chemically and will remain in the final clinical preparation. These Tc radionuclidic impurities are derived from nuclear interactions of the accelerated protons with other stable Mo isotopes present in the enriched (100)Mo target.